DE60117828D1 - Nanopartikel - Google Patents
NanopartikelInfo
- Publication number
- DE60117828D1 DE60117828D1 DE60117828T DE60117828T DE60117828D1 DE 60117828 D1 DE60117828 D1 DE 60117828D1 DE 60117828 T DE60117828 T DE 60117828T DE 60117828 T DE60117828 T DE 60117828T DE 60117828 D1 DE60117828 D1 DE 60117828D1
- Authority
- DE
- Germany
- Prior art keywords
- carbohydrate
- nanoparticles
- immobilising
- therapeutics
- studying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Ceramic Engineering (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- Theoretical Computer Science (AREA)
- Mathematical Physics (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0025414 | 2000-10-16 | ||
GBGB0025414.4A GB0025414D0 (en) | 2000-10-16 | 2000-10-16 | Nanoparticles |
PCT/GB2001/004633 WO2002032404A2 (en) | 2000-10-16 | 2001-10-16 | Nanoparticles |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60117828D1 true DE60117828D1 (de) | 2006-05-04 |
DE60117828T2 DE60117828T2 (de) | 2006-11-16 |
Family
ID=9901442
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60117828T Expired - Lifetime DE60117828T2 (de) | 2000-10-16 | 2001-10-16 | Nanopartikel |
DE60142192T Expired - Lifetime DE60142192D1 (de) | 2000-10-16 | 2001-10-16 | Nanopartikel |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60142192T Expired - Lifetime DE60142192D1 (de) | 2000-10-16 | 2001-10-16 | Nanopartikel |
Country Status (10)
Country | Link |
---|---|
US (3) | US7364919B2 (de) |
EP (2) | EP1671625B2 (de) |
JP (2) | JP4467882B2 (de) |
AT (2) | ATE319436T1 (de) |
AU (2) | AU2001294068B2 (de) |
CA (1) | CA2424734C (de) |
DE (2) | DE60117828T2 (de) |
ES (2) | ES2262684T3 (de) |
GB (1) | GB0025414D0 (de) |
WO (1) | WO2002032404A2 (de) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7871597B2 (en) | 1999-04-09 | 2011-01-18 | Amag Pharmaceuticals, Inc. | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
FI118061B (fi) * | 2001-09-24 | 2007-06-15 | Beanor Oy | Menetelmä ja bioanturi analyysiä varten |
FI115166B (fi) * | 2001-12-31 | 2005-03-15 | Biofons Oy | Diagnostisia menetelmiä |
JP4520857B2 (ja) * | 2002-09-20 | 2010-08-11 | インテル・コーポレーション | 走査型プローブ顕微鏡検査(spm)読取用の特定の情報をエンコードするナノバーコードの制御された整列 |
US7361821B2 (en) | 2002-09-20 | 2008-04-22 | Intel Corporation | Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (SPM) reading |
US7695738B2 (en) * | 2003-02-19 | 2010-04-13 | Academia Sinica | Carbohydrate encapsulated nanoparticles |
WO2005010481A2 (en) * | 2003-06-03 | 2005-02-03 | The Regents Of The University Of California | Preparation and use of gold glyconanoparticles |
GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
WO2005044861A1 (en) * | 2003-10-31 | 2005-05-19 | Wyeth Holdings Corporation | Polysaccharides of helicobacter pylori |
EP1687024B1 (de) * | 2003-11-05 | 2011-10-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Kohlenhydrat-antigen-nanoteilchen-konjugate und ihre verwendungen als antimetastatische mittel bei der behandlung von krebs |
ES2242528B1 (es) | 2004-03-25 | 2006-12-01 | Consejo Sup. Investig. Cientificas | Nanoparticulas magneticas de metales nobles. |
WO2005116226A2 (en) * | 2004-05-24 | 2005-12-08 | Midatech Ltd | Nanoparticles comprising rna ligands |
GB0411537D0 (en) * | 2004-05-24 | 2004-06-23 | Midatech Ltd | Nanoparticles comprising rna ligands |
US20070249063A1 (en) * | 2004-08-30 | 2007-10-25 | Deshong Philip R | Biosensors |
JP5117191B2 (ja) * | 2004-10-01 | 2013-01-09 | ミダテック リミテッド | 抗原及びアジュバントを含むナノ粒子、並びに免疫原性構造 |
JP4550555B2 (ja) * | 2004-11-17 | 2010-09-22 | 国立大学法人 東京医科歯科大学 | 量子ドット(Qdot)−ナノゲル複合体の調製 |
JP2006182673A (ja) * | 2004-12-27 | 2006-07-13 | Kenji Yamamoto | マーカー付き医薬 |
JP4484151B2 (ja) * | 2005-03-28 | 2010-06-16 | 国立大学法人滋賀大学 | ヒト血液型試薬 |
US9297092B2 (en) | 2005-06-05 | 2016-03-29 | Qd Vision, Inc. | Compositions, optical component, system including an optical component, devices, and other products |
US8845927B2 (en) | 2006-06-02 | 2014-09-30 | Qd Vision, Inc. | Functionalized nanoparticles and method |
WO2006135782A2 (en) * | 2005-06-10 | 2006-12-21 | Applera Corporation | Method and system for multiplex genetic analysis |
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
EP1919507A2 (de) * | 2005-08-04 | 2008-05-14 | Thomas William Rademacher | Nanoteilchen mit antibakteriellen liganden |
GB0517077D0 (en) * | 2005-08-19 | 2005-09-28 | Isis Innovation | Imaging agent |
JP4670659B2 (ja) * | 2006-01-25 | 2011-04-13 | 住友電気工業株式会社 | 蛍光標識金属粉末、ならびに該蛍光標識金属粉末を含有する異方導電膜、実装品 |
WO2008123844A2 (en) * | 2006-02-08 | 2008-10-16 | University Of Toledo | System for detecting nanoparticles using modulated surface plasmon resonance (mspr) |
US8849087B2 (en) * | 2006-03-07 | 2014-09-30 | Qd Vision, Inc. | Compositions, optical component, system including an optical component, devices, and other products |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
US9212056B2 (en) | 2006-06-02 | 2015-12-15 | Qd Vision, Inc. | Nanoparticle including multi-functional ligand and method |
US8329635B2 (en) * | 2006-06-20 | 2012-12-11 | Bracco Imaging S.P.A. | Method for the preparation of specific antibodies against saccharidic antigens |
WO2008063662A2 (en) * | 2006-11-21 | 2008-05-29 | Black Lion Pharmaceuticals | Gold (iii) chloride compositions for cancer |
CA2591496C (en) | 2006-12-18 | 2014-09-02 | Japan Science And Technology Agency | Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods |
US20080317768A1 (en) | 2007-06-21 | 2008-12-25 | Boeing Company | Bioconjugated nanoparticles |
ES2320837B1 (es) | 2007-07-26 | 2010-03-04 | Consejo Superior De Investigaciones Cientificas | Dispositivo de hipertermia y su utilizacion con nanoparticulas. |
US8916135B2 (en) | 2007-08-22 | 2014-12-23 | Colorado School Of Mines | Lanthanide nanoparticle conjugates and uses thereof |
EP2033660A1 (de) * | 2007-09-05 | 2009-03-11 | Freie Universität Berlin | Funktionalisierte Nanopartikel zur Hemmung Selectin-vermittelter Zelladhäsion |
GB0718843D0 (en) | 2007-09-26 | 2007-11-07 | Cancer Rec Tech Ltd | Materials and methods relating to modifying the binding of antibodies |
DE102007055386B4 (de) * | 2007-11-20 | 2015-07-16 | Boehringer Ingelheim Vetmedica Gmbh | Verfahren zur Kalibrierung eines Sensorelements |
CN101835556A (zh) * | 2007-12-28 | 2010-09-15 | 国立大学法人滋贺医科大学 | 金纳米粒子组合物、dna芯片、近红外线吸收材料、药物递送***(dds)用药物载体、着色剂、生物传感器、化妆品、生物体内诊断用组合物及治疗用组合物 |
EP2123269A1 (de) * | 2008-05-21 | 2009-11-25 | Freie Universität Berlin | Mit sulfatierten Aminalkoholen funktionalisierte Nanopartikel zur Hemmung selectinvermittelter Zelladhäsion |
US8968705B2 (en) * | 2008-08-22 | 2015-03-03 | Colorado School Of Mines | Gold/lanthanide nanoparticle conjugates and uses thereof |
EP2384439A4 (de) * | 2009-01-30 | 2013-06-05 | Univ Utah Res Found | Mit gold-nanopartikeln quervernetzte hydrogele |
WO2010138192A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Nanocarriers possessing components with different rates of release |
US20110110965A1 (en) | 2009-08-26 | 2011-05-12 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
EP2561072A4 (de) | 2010-04-20 | 2016-04-06 | Univ Florida | Nanozyme, verfahren zur herstellung von nanozymen und verfahren zur verwendung von nanozymen |
US8962345B2 (en) * | 2010-05-21 | 2015-02-24 | The United States Of America As Represented By The Secretary Of Commerce | Method of characterizing glycans attached to glycoproteins |
CA2798994A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
AU2011265294B2 (en) | 2010-06-10 | 2015-01-22 | Aquestive Therapeutics, Inc. | Nanoparticle film delivery systems |
CA2802031C (en) * | 2010-06-10 | 2015-05-12 | Midatech Limited | Peptide-carrying nanoparticles |
EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
KR20140034202A (ko) | 2011-04-29 | 2014-03-19 | 셀렉타 바이오사이언시즈, 인크. | 관용원성 합성 나노운반체 |
EP2736537A4 (de) | 2011-07-29 | 2015-04-15 | Selecta Biosciences Inc | Synthetische nanotransporter zur erzeugung humoraler und cytotoxischer t-lymphocy (ctl)-immunreaktionen |
JP5754309B2 (ja) * | 2011-09-02 | 2015-07-29 | コニカミノルタ株式会社 | 表面プラズモン励起増強蛍光分光法を利用して蛍光量を測定する定量分析方法ならびにそれに用いられる定量分析用キットおよびアナライト解離抑制剤 |
WO2013034726A1 (en) | 2011-09-07 | 2013-03-14 | Midatech Limited | Nanoparticle-peptide compositions |
CA2847907A1 (en) | 2011-09-07 | 2013-03-14 | Midatech Limited | Nanoparticle tumour vaccines |
US9772305B2 (en) | 2011-09-15 | 2017-09-26 | Arizona Board Of Regents On Behalf Of Arizona State University | System and method for small molecule detection |
GB201301991D0 (en) | 2013-02-05 | 2013-03-20 | Midatech Ltd | Permeation enhanced active-carrying nanoparticles |
GB201302427D0 (en) | 2013-02-12 | 2013-03-27 | Midatech Ltd | Nanoparticle delivery compositions |
GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
GB201303787D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticle peptide compositions |
WO2014145205A2 (en) | 2013-03-15 | 2014-09-18 | St. Jude Children's Research Hospital | Methods and compositions of p27kip1 transcription modulators |
KR101329646B1 (ko) | 2013-05-02 | 2013-11-14 | 주식회사 지니스 | 표적지향증폭형 항암나노입자 및 이의 제조방법 |
EP2991631A4 (de) * | 2013-05-03 | 2016-11-16 | Selecta Biosciences Inc | Tolerogene synthetische nanoträger und therapeutische makromoleküle für reduzierte oder verbesserte pharmakodynamische effekte |
BR112015030237A2 (pt) | 2013-06-04 | 2017-10-03 | Selecta Biosciences Inc | Imunoterapêutico antígeno-específico, composição, método de fabricação e seu uso |
WO2015023715A1 (en) | 2013-08-14 | 2015-02-19 | The University Of Florida Research Foundation, Inc. | Nanozymes, methods of making nanozymes, and methods of using nanozymes |
EP3049154B1 (de) | 2013-09-29 | 2019-11-13 | St. Jude Children's Research Hospital, Inc. | Arylsubstituierte aminomethyl-spectinomycin-analoga als antibakterielle mittel |
GB201401706D0 (en) | 2014-01-31 | 2014-03-19 | Midatech Ltd | Nanoparticle-insulin and insulin analogue compositions |
JP6789823B2 (ja) | 2014-04-15 | 2020-11-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 両末端peg化インテグリン結合性ペプチドおよびその使用方法 |
EA201692512A1 (ru) | 2014-06-25 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки |
US9910035B1 (en) | 2014-07-16 | 2018-03-06 | Verily Life Sciences Llc | Polyvalent functionalized nanoparticle-based in vivo diagnostic system |
KR20230053709A (ko) | 2014-09-07 | 2023-04-21 | 셀렉타 바이오사이언시즈, 인크. | 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물 |
EP3237016A1 (de) | 2014-12-23 | 2017-11-01 | Midatech Ltd | Nanopartikel und deren verwendung in der krebstherapie |
WO2016185935A1 (ja) * | 2015-05-18 | 2016-11-24 | 柿原秀己 | 抗菌物質及び液状抗菌剤並びに液状抗菌剤の製造方法 |
JP6902025B2 (ja) | 2015-06-18 | 2021-07-14 | ティン セラピューティックス エルエルシー | 聴覚損失の予防および治療のための方法および組成物 |
GB2541166A (en) | 2015-07-24 | 2017-02-15 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
JP7417354B2 (ja) | 2016-03-11 | 2024-01-18 | セレクタ バイオサイエンシーズ インコーポレーテッド | ペグ化ウリカーゼの処方物および用量 |
AU2017257189B2 (en) | 2016-04-29 | 2022-03-31 | Icahn School Of Medicine At Mount Sinai | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
US20180085319A1 (en) | 2016-09-27 | 2018-03-29 | Takashi Kei Kishimoto | Methods and compositions for treating cancer |
WO2018127689A1 (en) | 2017-01-03 | 2018-07-12 | Emergex Vaccines Holdings Ltd | Universal influenza vaccine compositions |
EP3565572A1 (de) | 2017-01-07 | 2019-11-13 | Selecta Biosciences, Inc. | Strukturierte dosierung von an synthetische nanoträger gekoppelten immunsuppressiva |
GB201701745D0 (en) | 2017-02-02 | 2017-03-22 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
MX2019010757A (es) | 2017-03-11 | 2020-01-20 | Selecta Biosciences Inc | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. |
US10543231B2 (en) | 2017-05-19 | 2020-01-28 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
GB2563602B (en) | 2017-06-19 | 2022-06-08 | Middlesex Univ Higher Education Corporation | Method and apparatus for imaging |
BR112020005565A2 (pt) | 2017-09-21 | 2020-10-06 | Emergex Vaccines Holding Limited | peptídeos associados a mhc de classe i para prevenção e tratamento de vírus zika |
JP7427584B2 (ja) | 2017-10-13 | 2024-02-05 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクターigm応答を減弱化するための方法および組成物 |
CN111565746A (zh) | 2018-01-06 | 2020-08-21 | 埃默杰克斯疫苗控股有限公司 | 用于预防和治疗多种黄病毒的mhc i类相关肽 |
WO2019186200A1 (en) | 2018-03-29 | 2019-10-03 | Emergex Vaccines Holding Limited | Vaccine compositions |
WO2019186199A1 (en) | 2018-03-29 | 2019-10-03 | Emergex Vaccines Holding Limited | Vaccine compositions |
CA3099643A1 (en) | 2018-05-18 | 2019-11-21 | Emergex Vaccines Holding Limited | Reverse peptide vaccine |
CN112654370A (zh) | 2018-07-16 | 2021-04-13 | 西莱克塔生物科技公司 | Mma构建体和载体的方法和组合物 |
CN112771070A (zh) | 2018-07-16 | 2021-05-07 | 西莱克塔生物科技公司 | Otc构建体和载体的方法和组合物 |
GB201819430D0 (en) | 2018-11-29 | 2019-01-16 | Midatech Ltd | Therapeutic compounds, nanoparticles and uses thereof |
GB201820471D0 (en) | 2018-12-14 | 2019-01-30 | Midatech Ltd | Nanoparticle-based therapy of inflammatory disorders |
GB201820470D0 (en) | 2018-12-14 | 2019-01-30 | Midatech Ltd | Antifolate-carrying nanoparticles and their use in medicine |
MX2021013163A (es) | 2019-04-28 | 2022-02-21 | Selecta Biosciences Inc | Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral. |
US20200390718A1 (en) | 2019-05-28 | 2020-12-17 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
CA3138071A1 (en) | 2019-06-04 | 2020-12-10 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
US11890299B2 (en) | 2019-06-27 | 2024-02-06 | Hologic, Inc. | Ablation agent and methods of use |
CA3158408A1 (en) | 2019-10-21 | 2021-04-29 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
CN110755640B (zh) * | 2019-10-21 | 2022-06-10 | 浙江师范大学 | 一种金铂复合纳米诊疗剂的制备方法及应用 |
AU2020380944A1 (en) | 2019-11-08 | 2022-06-02 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
KR20220111315A (ko) | 2019-12-18 | 2022-08-09 | 에프. 호프만-라 로슈 아게 | 연속 표지화 방식을 사용하는 합성에 의한 시퀀싱 방법 |
JP2023515202A (ja) | 2020-02-26 | 2023-04-12 | セレクタ バイオサイエンシーズ インコーポレーテッド | 免疫抑制薬を含む合成ナノキャリアを使用する方法および組成物 |
WO2021211100A1 (en) | 2020-04-14 | 2021-10-21 | Selecta Biosciences, Inc. | Methods and compositions for inducing autophagy |
GB202008250D0 (en) | 2020-06-02 | 2020-07-15 | Emergex Vaccines Holding Ltd | Diagnosis, prevention and treatment of coronavirus infection |
CN111590087B (zh) * | 2020-06-04 | 2023-04-18 | 安徽医科大学 | 荧光金纳米簇的制备方法、制得的荧光金纳米簇及其应用 |
EP4240400A1 (de) | 2020-11-04 | 2023-09-13 | Selecta Biosciences, Inc. | Zusammensetzungen zur verringerung der immunantworten gegen immunglobulinproteasen |
AU2022206197A1 (en) | 2021-01-05 | 2023-07-13 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
JP2024507808A (ja) | 2021-02-16 | 2024-02-21 | エマージェクス ヴァクシーンズ ホールディング リミテッド | 逆ペプチド |
CN113059177A (zh) * | 2021-03-05 | 2021-07-02 | 江苏师范大学 | 一种金/银/金核壳结构的纳米粒子及其合成方法 |
MX2023011004A (es) | 2021-03-19 | 2024-01-08 | Trained Therapeutix Discovery Inc | Compuestos para regular la inmunidad entrenada y métodos para usarlos. |
EP4319747A1 (de) | 2021-04-09 | 2024-02-14 | Selecta Biosciences, Inc. | Synthetische nanoträger mit einem immunsuppressivum in kombination mit hochaffinen il-2-rezeptoragonisten zur verbesserung der immuntoleranz |
WO2022253917A1 (en) | 2021-06-02 | 2022-12-08 | Emergex Vaccines Holding Limited | Human coronavirus 229e derived peptides |
CN113500199B (zh) * | 2021-06-10 | 2022-11-08 | 浙江大学 | 一种基于金铂双金属活性氧自生成纳米材料的制备方法及其产品和应用 |
WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
CA3235269A1 (en) | 2021-10-12 | 2023-04-20 | Cartesian Therapeutics, Inc. | Viral vector dosing protocols |
CA3237037A1 (en) | 2021-11-14 | 2023-05-19 | Cartesian Therapeutics, Inc. | Multiple dosing with viral vectors |
US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
US20230322884A1 (en) | 2022-03-09 | 2023-10-12 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
WO2023183568A1 (en) | 2022-03-25 | 2023-09-28 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents |
WO2023196566A1 (en) | 2022-04-08 | 2023-10-12 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
US20240148841A1 (en) | 2022-08-11 | 2024-05-09 | Selecta Biosciences Inc. | Compositions and methods related to immunoglobulin proteases and fusions thereof |
WO2024107889A1 (en) | 2022-11-15 | 2024-05-23 | Selecta Biosciences, Inc. | Compositions and methods for treating primary biliary cholangitis |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7807532A (nl) * | 1978-07-13 | 1980-01-15 | Akzo Nv | Metaal-immunotest. |
WO1983000173A1 (en) | 1981-07-02 | 1983-01-20 | Eynon, David, Leslie | Flow box |
US4501726A (en) * | 1981-11-12 | 1985-02-26 | Schroeder Ulf | Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof |
SE8704157L (sv) | 1987-10-26 | 1989-04-27 | Carbomatrix Ab C O Ulf Schroed | Superparamagnetiska partiklar och foerfarande foer framstaellning daerav samt anvaendning |
US5178882A (en) | 1990-06-22 | 1993-01-12 | The Regents Of The University Of California | Viral decoy vaccine |
US5248772A (en) * | 1992-01-29 | 1993-09-28 | Coulter Corporation | Formation of colloidal metal dispersions using aminodextrans as reductants and protective agents |
DE69324591T3 (de) * | 1992-08-05 | 2004-02-12 | Meito Sangyo K.K., Nagoya | Verbundmaterial mit kleinem durchmesser, welches ein wasserlösliches carboxylpolysaccharid und magnetisches eisenoxid enthaltet |
WO1995031220A1 (fr) * | 1994-05-12 | 1995-11-23 | Otsuka Pharmaceutical Co., Ltd. | Agent de contraste pour imagerie par resonance magnetique |
FR2777193B1 (fr) * | 1998-04-14 | 2001-06-08 | Coletica | Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie |
AU6016999A (en) * | 1998-04-20 | 1999-12-13 | University Of North Carolina At Chapel Hill, The | Nanometer sized particles containing a reactive monolayer adsorbed thereon and methods of making the same |
WO2001073123A2 (en) | 2000-03-28 | 2001-10-04 | Nanosphere Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
-
2000
- 2000-10-16 GB GBGB0025414.4A patent/GB0025414D0/en not_active Ceased
-
2001
- 2001-10-16 CA CA2424734A patent/CA2424734C/en not_active Expired - Lifetime
- 2001-10-16 JP JP2002535642A patent/JP4467882B2/ja not_active Expired - Lifetime
- 2001-10-16 AT AT01974554T patent/ATE319436T1/de active
- 2001-10-16 ES ES01974554T patent/ES2262684T3/es not_active Expired - Lifetime
- 2001-10-16 WO PCT/GB2001/004633 patent/WO2002032404A2/en active IP Right Grant
- 2001-10-16 AU AU2001294068A patent/AU2001294068B2/en not_active Expired
- 2001-10-16 EP EP05026069.4A patent/EP1671625B2/de not_active Expired - Lifetime
- 2001-10-16 AT AT05026069T patent/ATE468112T1/de active
- 2001-10-16 US US10/399,284 patent/US7364919B2/en not_active Expired - Lifetime
- 2001-10-16 EP EP01974554A patent/EP1326589B1/de not_active Expired - Lifetime
- 2001-10-16 DE DE60117828T patent/DE60117828T2/de not_active Expired - Lifetime
- 2001-10-16 DE DE60142192T patent/DE60142192D1/de not_active Expired - Lifetime
- 2001-10-16 ES ES05026069.4T patent/ES2346319T5/es not_active Expired - Lifetime
- 2001-10-16 AU AU9406801A patent/AU9406801A/xx active Pending
-
2008
- 2008-02-29 US US12/040,594 patent/US8080431B2/en not_active Expired - Fee Related
-
2009
- 2009-06-24 JP JP2009150219A patent/JP2009242418A/ja active Pending
-
2011
- 2011-11-29 US US13/306,924 patent/US8790934B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8080431B2 (en) | 2011-12-20 |
US20120071443A1 (en) | 2012-03-22 |
ES2262684T3 (es) | 2006-12-01 |
EP1671625A1 (de) | 2006-06-21 |
JP2009242418A (ja) | 2009-10-22 |
CA2424734C (en) | 2011-10-11 |
GB0025414D0 (en) | 2000-11-29 |
JP4467882B2 (ja) | 2010-05-26 |
CA2424734A1 (en) | 2002-04-25 |
JP2004511511A (ja) | 2004-04-15 |
WO2002032404A2 (en) | 2002-04-25 |
AU2001294068B2 (en) | 2005-12-22 |
ES2346319T5 (es) | 2014-03-18 |
US20080145441A1 (en) | 2008-06-19 |
EP1671625B2 (de) | 2013-12-25 |
ATE468112T1 (de) | 2010-06-15 |
AU9406801A (en) | 2002-04-29 |
EP1326589A2 (de) | 2003-07-16 |
US20040052729A1 (en) | 2004-03-18 |
US7364919B2 (en) | 2008-04-29 |
DE60142192D1 (de) | 2010-07-01 |
EP1326589B1 (de) | 2006-03-08 |
WO2002032404A3 (en) | 2002-08-22 |
DE60117828T2 (de) | 2006-11-16 |
US8790934B2 (en) | 2014-07-29 |
ATE319436T1 (de) | 2006-03-15 |
ES2346319T3 (es) | 2010-10-14 |
EP1671625B1 (de) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60142192D1 (de) | Nanopartikel | |
DK1631318T3 (da) | Magnetiske nanopartikler bundet til en ligand | |
ATE236656T1 (de) | Eingeschränktes multifunktionelles reagens zur oberflächenmodifikation | |
ATE378399T1 (de) | Magnetische manipulation von biologischen proben | |
DE69434871D1 (de) | Erhöhung von Chemilumineszenz in Assays | |
ATE412774T1 (de) | Parallele genotypisierung mehrerer patientenproben | |
ATE437888T1 (de) | Aus chaperonin-polypeptiden gebildete geordnete biologische nanostrukturen | |
ATE160818T1 (de) | Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit | |
ATE354607T1 (de) | Opake folie aus polymilchsäuren | |
JP2005513440A5 (de) | ||
ATE334393T1 (de) | Ligand-anker-konjugate zur generierung einer biosensor-schicht | |
DE50107918D1 (de) | Alkoholgemische mit 13 und 15 kohlenstoffatomen und deren verwendung in der herstellung von oberflächenaktiven substanzen | |
Lard et al. | Molecular motor transport through hollow nanowires | |
DE50206263D1 (de) | Vorrichtung zur halterung eines substanzbibliothekenträgers | |
BR9913444A (pt) | Suporte em forma de pelìcula para uma substância ativa, processo para sua fabricação e sua utilização | |
DE50300739D1 (de) | Vorrichtung zur aufnahme von substraten | |
ATE430712T1 (de) | Analyse von molekülen durch translokation durch eine beschichtete öffnung | |
ATE70916T1 (de) | Mit ueberzuegen versehene formkoerper zur bindung von bioaffinen substanzen. | |
DE602004005158D1 (de) | Oberflächenschichtsaffinitätschromatographie | |
SE0001660D0 (sv) | Separation of glyco-containing entities | |
DE60133937D1 (de) | Vorrichtung zur Herstellung von Mikromatrizen wobei die Vorrichtung in inkrementellen Etappen mechanisch eingestellt wird | |
DE69115518D1 (de) | Verfahren zur Abtrennung und Messung von Spurbestandteilen | |
DE69214244D1 (de) | Monoklonale Antikörper gegen sulfonierte Polymere | |
Bhardwaj | The miospore genera in the coals of Raniganj stage (Upper Permian), India | |
Eun-Min | A study on the ego-resilience and social adaptability of the children and adolescence in institutional care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |